Current Report Filing (8-k)
February 08 2019 - 3:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of Earliest Event Reported):
July 19,
2017
CYBRDI, INC.
(Name
of Small Business Issuer in its Charter)
California
|
95-2461404
|
(State or Jurisdiction of Incorporation or
|
(I.R.S. Employer Identification No.)
|
Organization)
|
|
29 Changan South Road, Yanta District
Xian
City, Shaanxi Province, China 710061
(Address of principal
executive offices)
+86 029-88103388
(Telephone Number of
Principal Executive Offices)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Item 1.01
|
Entry into a Material Definitive
Agreement
|
On July 19, 2017, Cybrdi. Inc. (the Company) entered into a
share transfer agreement (the Agreement) with Xian Alena Biotechnology Co.,
Ltd (the Purchaser). Neither the Company nor its affiliates have any material
relationship with the Purchaser other than with respect to the Agreement.
Pursuant to the Agreement, the Company agreed to sell its 80%
equity interest in Shaanxi Chaoying Biotechnology Co., Ltd (the Target) for a
consideration of 25.6 million RMB (approximately $3.8 million).
The Purchaser paid the Company 47% of the consideration under
the Agreement by December, 2017, after the Target and the Company had completed
the necessary regulatory registration procedures, and is expected to pay the
balance of the consideration.
The other shareholders of the Target, Shannxi Yanfeng Real
Estate Development Co., Ltd, Shannxi Chaoying Cosmetics Co., Ltd, and
Immuno-Oncocemomics Inc. had given up their respective rights of first refusal
to purchase the equity interest held by the Company in the Target.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 4, 2019
|
CYBRDI, INC.
|
|
|
|
|
By:
|
/s/
Yanbiao Bai
|
|
|
Name: Yanbiao Bai
|
|
|
Title: Chief Executive Officer
|